VEGFA and neoplasm: The analysis of ligand‐receptor interactions in tumour stage unveiled distinct crosstalk between T cells and myeloid cells, B cells, and tumour cells, featuring enhanced engagement of immune inhibitory or immune checkpoint synergistic pathways such as VEGF, CXCL and GALECTIN104, 105, 106 (Figure S9E–N).